Using focused ultrasound to enhance cancer therapies for breast cancer
Immunoengineering Next-Generation Cancer Therapies with Focused Ultrasound
This study is looking at how using focused ultrasound can help boost the effectiveness of immunotherapy for people with metastatic breast cancer, with the hope of improving their immune response to fight the cancer better.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Virginia NIH-funded |
| Lab location | 1 site (Charlottesville, United States) |
| Project ID | NIH-10918169 on NIH RePORTER |
What this research studies
This research investigates how focused ultrasound (FUS) can improve the effectiveness of immunotherapy for metastatic breast cancer, a condition with a low survival rate. The approach involves using non-invasive ultrasound to stimulate the immune system, potentially increasing the body's ability to fight cancer. The study will assess the combination of FUS with existing immunotherapies, aiming to enhance immune responses against breast cancer metastases. Patients may also participate in clinical trials that monitor immune cell activity in response to these treatments.
Who could benefit from this research
Good fit: Ideal candidates for this research are women diagnosed with metastatic breast cancer who are seeking innovative treatment options.
Not a fit: Patients with early-stage breast cancer or those who have not been diagnosed with breast cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for patients with metastatic breast cancer.
How similar studies have performed: Previous research has shown promising results in combining focused ultrasound with immunotherapy in other cancer types, indicating potential for success in this novel application.
Where this research is happening
Charlottesville, United States
- University of Virginia — Charlottesville, United States (Active)
Researchers
- Principal investigator: Sheybani, Natasha Diba — University of Virginia
- Study coordinator: Sheybani, Natasha Diba
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.